A recent study in Nature Medicine found that LM11A-31, targeting the p75 neurotrophin receptor, is safe and shows promise in slowing Alzheimer’s disease progression. The trial indicated significant biomarker improvements and potential benefits for further clinical investigation.
FDA concerned Cardinal Health failed to mitigate risk of incompatible syringes
Dive Brief: The Food and Drug Administration voiced concerns in a Monday letter that Cardinal Health failed to sufficiently mitigate the risk of incompatibility between its syringes
November 21, 2023